Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Neoplasms 2Melanoma 2Warts 1Recurrence 1Papilloma 1Neoplasm Metastasis 1Leukemia, Myeloid, Chronic-Phase 1Leukemia 1Kidney Neoplasms 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Dexamethasone 64Lenalidomide 34pomalidomide 33Cyclophosphamide 33Rituximab 31Bortezomib 29venetoclax 27fludarabine 26Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 16Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Injections 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × Interferon-alpha × Clear all
NCT00329368 2012-03-09

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Endocyte

Phase 1 Completed
13 enrolled

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡